• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Slovakia Pharmaceuticals and Healthcare Report Q4 2012 - Product Image

Slovakia Pharmaceuticals and Healthcare Report Q4 2012

  • Published: November 2012
  • Region: Slovakia
  • 86 pages
  • Business Monitor International

FEATURED COMPANIES

  • Biotika
  • GlaxoSmithKline
  • Local Companies
  • Multinational Companies
  • Pfizer
  • Sanofi
  • MORE

BMI View:

The new Prime Minister Robert Fico has indicated that he is willing to pursue the idea of completely removing private firms from the public health insurance market, causing alarm among some observers. While the language used by Fico may be alarming to some investors, we think it unlikely that Fico's drive to consolidate state power in welfare provision would extend into other sectors of the economy. As a result, we expect the impact of the announcement to be largely immaterial to foreign investment in Slovakia, which is largely channelled towards the industrial and banking sectors.

Headline Expenditure Projections:

- Pharmaceuticals: EUR1.72bn (US$2.45bn) in 2011 to EUR1.65bn (US$2.728bn) in 2012; -3.9%
in local currency terms and -7.3% in US dollar terms. Forecast unchanged from Q312.

- Healthcare: EUR5.97bn (US$8.53bn) in 2011 to EUR6.11bn (US$8.44bn) in 2012; +2.5% in local currency terms and -1.1% in US dollar terms. Forecast broadly unchanged from Q312.

- Medical devices: EUR384mn (US$550mn) in 2011 to EUR396mn (US$546) in 2012; +3.0% in local currency terms and -0.6% in US dollar terms. Forecast broadly unchanged from Q312.

Risk/Reward READ MORE >

Executive Summary 5

SWOT Analysis 7

Slovakia Pharmaceuticals Industry SWOT 7

Slovakia Political SWOT 8

Slovakia Economic SWOT 8

Slovakia Business Environment SWOT 8

Pharmaceutical Risk/Reward Ratings 10
Table: Central And Eastern Europe Pharmaceutical Risk/Rewards Ratings, Q412 10

Rewards 11

Risks 11

Slovakia – Market Summary 13

Regulatory Regime 14

Intellectual Property Regime 15

Pricing Regime 16
Table: Indexed Price Build-Up For Prescription And Non-Prescription Medicines In Slovakia 16

Reimbursement Regime 17

Pricing And Reimbursement Developments 18

Pharmaceutical Promotion 20

Industry Trends And Developments 22

Epidemiology 22
Table: Main Causes Of Mortality And Morbidity In Slovakia 23

Healthcare Sector 24

Recent Healthcare Sector Developments 25

Health Insurance 25

Private Health Insurance 26

Research & Development 27

Clinical Trials 28

Medical Device Market 28
Table: EU Medical Devices Classifications 28

Industry Forecast Scenario 30

Overall Market Forecast 30
Table: Pharmaceutical Sales, 2008-2016 32

Healthcare Market Forecast 33
Table: Overall Healthcare Expenditure, 2008-2016 34
Table: Governmental Healthcare Expenditure, 2008-2016 34
Table: Private Healthcare Expenditure, 2008-2016 35

Key Growth Factors – Macroeconomic 36

Prescription Drug Market Forecast 38
Table: Leading OTC Medicines in Slovakia, by 2011 Volume- 39
Table: Prescription Drug Sales, 2008-2016 40

Patented Drug Market Forecast 41
Table: Patented Drug Sales, 2008-2016 42

Generic Drug Market Forecast 43
Table: Generic Drug Sales, 2008-2016 44

OTC Medicine Market Forecast 45
Table: Leading Prescription Medicines in Slovakia, by 2011 Volume 46
Table: OTC Medicine Sales, 2008-2016 46
Table: OTC Medicine Sales Breakdown, 2004-2009 47

Pharmaceutical Trade Forecast 48
Table: Pharmaceutical Trade, 2008-2016 49

Medical Device Market Forecast 50
Table: Medical Device Sales, 2008-2016 51

Other Healthcare Data Forecasts 52

Key Risks To our Forecast Scenario 54

Competitive Landscape 55

Pharmaceutical Industry 55

Pharmaceutical Distribution 56

Company Profiles 59

Local Companies 59

Zentiva (Sanofi/Sicomed) 59

Biotika 62

HBM Pharma (formerly Hoechst-Biotika) 64

Imuna Pharma 66

Multinational Companies 68

GlaxoSmithKline 68

Sanofi 69

Pfizer 71

Novartis 73

Merck & Co 74

Roche 75

Demographic Outlook 76
Table: Population By Age Group, 1990-2020 ('000) 77
Table: Population By Age Group, 1990-2020 (% of total) 78
Table: Key Population Ratios, 1990-2020 79
Table: Rural/Urban Population Split, 1990-2020 79

Glossary 80

BMI Methodology 82

How We Generate Our Pharmaceutical Industry Forecasts 82

Pharmaceutical Risk/Reward Ratings Methodology 83

Ratings Overview 83
Table: Pharmaceutical Business Environment Indicators 84

Weighting 85
Table: Weighting Of Components 85

Sources 85

Company Profiles
Local Companies
Zentiva (Sanofi/Sicomed)
Biotika
HBM Pharma (formerly Hoechst-Biotika)
Imuna Pharma
Multinational Companies
GlaxoSmithKline
Sanofi
Pfizer
Novartis
Merck & Co
Roche

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos